| 前收市價 | 2.9000 |
| 開市 | 2.8100 |
| 買盤 | 2.8600 |
| 賣出價 | 2.9800 |
| 拍板 | 16.00 |
| 到期日 | 2025-01-17 |
| 今日波幅 | 2.8100 - 2.8800 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 3.29k |
ReutersTeva sues Corcept over mifepristone 'monopoly' for rare disorder
Teva Pharmaceuticals sued rival drugmaker Corcept Therapeutics in federal court in San Francisco on Thursday, accusing it of monopolizing the market for mifepristone-based Korlym, used to treat a rare hormonal disorder called Cushing's syndrome. The lawsuit said Corcept and specialty pharmacy Optime Care, the sole distributor of Korlym, orchestrated “a multifaceted scheme to prolong Corcept’s monopoly by stifling competition from Teva at every turn.” Teva accused Corcept of "paying bribes and kickbacks" to physicians to keep them prescribing brand Korlym.
ZacksTEVA Stock Rises 135% in a Year: What's Driving the Recovery?
TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.
InvestorPlacePatent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
Several drug stocks are at risk as the Federal Trade Commission is going after pharmaceutical companies that it alleges are trying to keep generic drugs at bay from their branded products. The Biden administration is attacking businesses across the board, such as its recent assault on the oil industry. Yet it risks killing off the drug discovery market with its actions by disincentivizing companies to find new treatments. For example, inventors of technology developed with federal funding retain
